![Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - ScienceDirect Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500222000381-gr1.jpg)
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - ScienceDirect
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile](https://i1.rgstatic.net/ii/profile.image/359041135071232-1462613485394_Q512/Mustafa-Oezgueroglu.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile
![Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - Lung Cancer Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - Lung Cancer](https://www.lungcancerjournal.info/cms/asset/41a9cefe-73ec-4bcd-998b-5bcf28f86c98/gr2.jpg)
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) - Lung Cancer
KANSER KEMOTERAPİSİ UYGULAMA İLKELERİ, Fuat H. Demirelli Mustafa Özgüroğlu Gökh - İkinci El Kitap - kitantik | #4522107000297
Mustafa Özgüroğlu - Professor of Medical Oncology - Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine | LinkedIn
Mustafa Özgüroğlu - Professor of Medical Oncology - Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine | LinkedIn
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-contr
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit | Research profile](https://www.researchgate.net/publication/351409175/figure/tbl2/AS:1024793168064519@1621341139945/Treatment-emergent-Adverse-Events-Any-Grade-in-10-of-Total-Population-Related-to_Q320.jpg)